
English (Google Machine Translation, Unedited)

Confirmed antiviral effect of Kowa ivermectin on "Omicron strain"

PRESS RELEASE

January 31, 2022

To everyone

Kowa Co., Ltd. (hereinafter referred to as "Kowa") has announced that the investigational drug "ivermectin" used in Phase III clinical trials (development code: K-237) for the treatment of new coronavirus (SARS-CoV-2) infection. From a joint research (non-clinical trial) with Kitasato University, it was confirmed that the same antiviral effect is applied to the Omicron strain as well as the existing mutant strain (alpha beta gamma delta strain). ..

As announced in July 2021, Kowa directly from Professor Satoshi Omura, a special honorary professor at Kitasato University, who won the Nobel Prize in Physiology or Medicine, about conducting clinical trials of ivermectin as a therapeutic drug for new coronavirus infections. I received a request. We believe that it is the mission of pharmaceutical companies to contribute to the treatment of new coronavirus infections and protect the health of the people, and conduct clinical trials to confirm the efficacy and safety of ivermectin against new coronavirus infections. doing.

Ivermectin has been distributed by WHO to infected areas for over 30 years as a treatment for parasitic infections. Especially in some African countries, it has been confirmed to be safe enough for volunteers to distribute directly to people. In addition, ivermectin has been reported to suppress the invasion of SARS-CoV-2 into cells and inhibit replication, and is expected to be applied as a new coronavirus infection therapeutic drug (tablet) for drug repositioning. .. In this clinical trial, the dosage and administration are different from those already approved for the treatment of parasitic infections, but the efficacy and safety are being confirmed in the clinical trial.

Kowa will contribute to the treatment of new coronavirus infections by confirming the clinical effect of ivermectin on SARS-CoV-2 and providing it to the public as soon as possible.

- Overseas, it was reported that patients use high-content ivermectin for animals, which is dangerous for humans, and adverse events occur. (Good Clinical Practice) "is conducting clinical trials of ivermectin in accordance with strict standards.

That's all

Public Relations Department (Tokyo) 3-4-14 Nihonbashihoncho, Chuo-ku, Tokyo

TEL: 03-3279-7392

Main store (Nagoya) 3-6-29 Nishiki, Naka-ku, Nagoya

EchoLight

You must include www

<https://www.kowa.co.jp/news/2022/press220131.pdf>

Archived (JP text):

<https://files.catbox.moe/wtidbt.pdf>